Cool article in the New Yorker titled "Superbugs" by Jerome Groopman for those of us interested in medical technology and healthcare.
Superbugs are short hand for the new breed of bacteria that are becoming resistant to traditional antibiotics. This is a huge problem but a big opportunity for medical technology companies. Shortly before I interned at Becton Dickinson in 2006, they acquired GeneOhm, a startup that screened for MRSA, a special kind of superbug. Congrats to BD for seeing the opportunity, acquiring the startup and accelerating the technology rollout. MRSA is just one kind of superbug, but it's a start.
In addition to diagnostics (GeneOhm), the world needs pharmaceuticals that can squash these bugs. The article runs through a few new treatments, but one get's the sense that even more are needed.